Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study

Schizophrenia Research

Volumn 174, Issue 1-3, 2016, Pages 137-143

  Chou, Po Han ^a,b   Chu, Che Sheng ^a   Lin, Ching Heng ^a   Cheng, Chin ^c   Chen, Yi Huey ^a   Lan, Tsuo Hung ^a,b   Huang, Min Wei ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Cataract; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; STEROID; ZIPRASIDONE; ZOTEPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CATARACT; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; GLAUCOMA; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA DISEASE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; TAIWAN; COMPLICATION; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CATARACT; COMORBIDITY; FEMALE; GLAUCOMA; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RETINAL DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 84962473500     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.03.027     Document Type: Article

References (46)

1. Boerrigter R.M., Siertsema J.V., Kema I.P. Serotonin (5-HT) and the rat's eye. Some pilot studies. Documenta ophthalmologica. Adv. Ophthalmol. 1992, 82(1-2):141-150.
2. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40(5):373-383.
3. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., Yeh H.H., Chen C.H., Tsai H.J. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
4. Chien I.C., Bih S.H., Chou Y.J., Lin C.H., Lee W.G., Chou P. Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatr. Serv. 2007, 58(4):554-557.
5. Chou P.H., Koike S., Nishimura Y., Satomura Y., Kinoshita A., Takizawa R., Kasai K. Similar age-related decline in cortical activity over frontotemporal regions in schizophrenia: a multichannel near-infrared spectroscopy study. Schizophr. Bull. 2015, 41(1):268-279.
6. Chou P.H., Lin C.H., Cheng C., Chang C.L., Tsai C.J., Tsai C.P., Lan T.H., Chan C.H. Risk of depressive disorders in women undergoing hysterectomy: a population-based follow-up study. J. Psychiatr. Res. 2015, 68:186-191.
7. Chou P.H., Lin W.H., Lin C.C., Hou P.H., Li W.R., Hung C.C., Lin C.P., Lan T.H., Chan C.H. Duration of untreated psychosis and brain function during verbal fluency testing in first-episode schizophrenia: a near-infrared spectroscopy study. Sci. Rep. 2015, 5:18069.
8. Chou P.H., Koike S., Nishimura Y., Kawasaki S., Satomura Y., Kinoshita A., Takizawa R., Kasai K. Distinct effects of duration of untreated psychosis on brain cortical activities in different treatment phases of schizophrenia: a multi-channel near-infrared spectroscopy study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 49:63-69.
9. Chou P.H., Lin C.C., Lin C.H., Loh el W., Chan C.H., Lan T.H. Prevalence of allergic rhinitis in patients with attention-deficit/hyperactivity disorder: a population-based study. Eur. Child Adolesc. Psychiatry 2013, 22(5):301-307.
10. Chou P.H., Lin C.C., Lin C.H., Tsai C.J., Cheng C., Chuo Y.P., Chan C.H., Lan T.H. Prevalence of gastroesophageal reflux disease in major depressive disorder: a population-based study. Psychosomatics 2014, 55(2):155-162.
11. Chou P.H., Lin C.H., Loh el W., Chan C.H., Lan T.H. Panic disorder and risk of stroke: a population-based study. Psychosomatics 2012, 53(5):463-469.
12. Chou F.H., Tsai K.Y., Su C.Y., Lee C.C. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr. Res. 2011, 129(2-3):97-103.
13. Costagliola C., Parmeggiani F., Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 2004, 18(8):475-484.
14. Cumming R.G., Mitchell P. Alcohol, smoking, and cataracts: the Blue Mountains eye study. Arch. Ophthalmol. 1997, 115(10):1296-1303.
15. Durrani O.M., Tehrani N.N., Marr J.E., Moradi P., Stavrou P., Murray P.I. Degree, duration, and causes of visual loss in uveitis. Br. J. Ophthalmol. 2004, 88(9):1159-1162.
16. El Sanharawi M., Basli E., Sandali O., Laroche L. The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J. Ophthalmol. 2014, 157(3):746.
17. Erie J.C., Brue S.M., Chamberlain A.M., Hodge D.O. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J. Ophthalmol. 2014, 158(1):192-197. e191.
18. Ernst P., Baltzan M., Deschenes J., Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur. Respir. J. 2006, 27(6):1168-1174.
19. Etminan M., Mikelberg F.S., Brophy J.M. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. Ophthalmology 2010, 117(6):1251-1255.
20. Fraunfelder F.W. Twice-yearly exams unnecessary for patients taking quetiapine. Am J. Ophthalmol. 2004, 138(5):870-871.
21. Greiner A.C., Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can. Med. Assoc. J. 1964, 90:663-665.
22. Harding J.J., Egerton M., van Heyningen R., Harding R.S. Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case control studies. Br. J. Ophthalmol. 1993, 77(1):2-6.
23. Hung Y.P., Liu C.J., Tsai C.F., Hung M.H., Tzeng C.H., Liu C.Y., Chen T.J. Incidence and risk of mood disorders in patients with breast cancers in Taiwan: a nationwide population-based study. Psycho-Oncology 2013, 22(10):2227-2234.
24. Klein B.E., Klein R., Lee K.E., Danforth L.G. Drug use and five-year incidence of age-related cataracts: the Beaver Dam eye study. Ophthalmology 2001, 108(9):1670-1674.
25. Laties A.M., Dev V.J., Geller W., Rak I., Brecher M., Nasrallah H. Safety update on lenticular opacities: benign experience with 620,000 US patient exposures to quetiapine. Abstracts of the 39th Annual Meeting of the American College of Neuropsychopharmacology 2000, ACNP, Nashville, Tennessee.
26. Laties A.M., Flach A.J., Baldycheva I., Rak I., Earley W., Pathak S. Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. J. Psychopharmacol. 2015, 29(1):69-79.
27. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., Clinical Antipsychotic Trials of Intervention Effectiveness, I. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
28. Maher A.R., Maglione M., Bagley S., Suttorp M., Hu J.H., Ewing B., Wang Z., Timmer M., Sultzer D., Shekelle P.G. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306(12):1359-1369.
29. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T., Friedman A., Kleinberg D., Yevich S.J., Davis B., Shon S. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 2004, 161(8):1334-1349.
30. McCarty C.A., Wood C.A., Fu C.L., Livingston P.M., Mackersey S., Stanislavsky Y., Taylor H.R. Schizophrenia, psychotropic medication, and cataract. Ophthalmology 1999, 106(4):683-687.
31. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30:67-76.
32. Mitchell P., Cumming R.G., Attebo K., Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology 1997, 104(4):581-588.
33. Nasrallah H.A., Dev V., Rak I., Raniwalla J. Safety update with quetiapine and lenticular examinations: experience with 300,000 patients. Abstracts of the 38th Annual Meeting of the American College of Neuropsychopharmacology 1999, Am Colleg Neuropharmacol, Nashville, Tennessee.
34. Pakzad-Vaezi K.L., Etminan M., Mikelberg F.S. The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J. Ophthalmol. 2013, 156(6):1141-1146. e1141.
35. Richa S., Yazbek J.C. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010, 24(6):501-526.
36. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 1999, 60(Suppl. 10):5-14.
37. Richter G.M., Torres M., Choudhury F., Azen S.P., Varma R., Los Angeles Latino Eye Study, G. Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino Eye Study. Ophthalmology 2012, 119(3):547-554.
38. Rowe N.G., Mitchell P.G., Cumming R.G., Wans J.J. Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains eye study. Ophthalmic Epidemiol. 2000, 7(2):103-114.
39. Ruigomez A., Garcia Rodriguez L.A., Dev V.J., Arellano F., Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?. Epidemiology 2000, 11(6):620-623.
40. Shahzad S., Suleman M.I., Shahab H., Mazour I., Kaur A., Rudzinskiy P., Lippmann S. Cataract occurrence with antipsychotic drugs. Psychosomatics 2002, 43(5):354-359.
41. Souza V.B., Moura Filho F.J., Souza F.G., Rocha C.F., Furtado F.A., Goncalves T.B., Vasconcelos K.F. Cataract occurrence in patients treated with antipsychotic drugs. Rev. Bras. Psiquiatr. 2008, 30(3):222-226.
42. Thompson J.T., Glaser B.M., Sjaarda R.N., Murphy R.P. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J. Ophthalmol. 1995, 119(1):48-54.
43. Ucok A., Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008, 7(1):58-62.
44. Vivekanandan S., Lou M.F. Evidence for the presence of phosphoinositide cycle and its involvement in cellular signal transduction in the rabbit lens. Curr. Eye Res. 1989, 8(1):101-111.
45. Whitehorn D., Gallant J., Woodley H., Rui Q., Milliken H., Kopala L. Quetiapine treatment in early psychosis: no evidence of cataracts. Schizophr. Res. 2004, 71(2-3):511-512.
46. Wong T.Y., Loon S.C., Saw S.M. The epidemiology of age related eye diseases in Asia. Br. J. Ophthalmol. 2006, 90(4):506-511.